AIMC Journal:
Molecular therapy. Oncology

Breast cancer patients with estrogen receptor-negative (ERneg) status, encompassing triple negative breast cancer (TNBC) and human epidermal growth factor receptor 2 positive breast cancer, are confronted with a heightened risk of drug resistance, of...

Epithelial ovarian cancer remains one of the deadliest gynecologic malignancies, with late-stage diagnosis, high recurrence rates, and resistance to platinum-based chemotherapy contributing to poor survival outcomes. Central to the effective manageme...